Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection

V. Nehra, E. M. Tan, Stacey Rizza, Zelalem Temesgen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Hepatitis C virus (HCV) genotype 4 accounts for 8-13% of all chronic HCV infections worldwide. Patients with HCV genotype 4 have been reported to have poor treatment responses to PEGylated interferon and ribavirin regimens. Recently a single tablet, fixed-dose combination ofsofos- buvir, an RNA-directed RNA polymerase (NS5B) inhibitor, and ledipasvir, a nonstructural protein 5A (NS5A) inhibitor; has been approved for treatment of chronic HCV infection. Two studies using the fixed-dose combination in chronic HCV genotype 4 for 12 weeks reported sustained virologic response rates at 12 weeks (SVR12) of 93-95%. Data also support the use of ledipasvir/sofosbuvir in chronic HCV genotype 4 and HIV co-infection. Administered as a single once-daily oral regimeni, this ribavirin- And interferon-free regimen is well tolerated, with low potential for adverse effects and represents a significant advancement in the treatment of chronic HCV genotype 4 infection.

Original languageEnglish (US)
Pages (from-to)111-117
Number of pages7
JournalDrugs of Today
Volume52
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Hepacivirus
Chronic Hepatitis C
Genotype
Infection
Ribavirin
Virus Diseases
Interferons
Therapeutics
RNA Replicase
sofosbuvir drug combination ledipasvir
Coinfection
Tablets
HIV Infections
Proteins

Keywords

  • Directed RNA polymerase (NS5B) inhibitors
  • Fixed-dose combination
  • HCV nonstructural protein 5A (NS5A) inhibitors
  • Hepatitis C virus
  • Ledipasvir/sofosbuvir
  • RNA

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection. / Nehra, V.; Tan, E. M.; Rizza, Stacey; Temesgen, Zelalem.

In: Drugs of Today, Vol. 52, No. 2, 01.02.2016, p. 111-117.

Research output: Contribution to journalArticle

@article{98e0d97c3d7b4740abc7205084448483,
title = "Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection",
abstract = "Hepatitis C virus (HCV) genotype 4 accounts for 8-13{\%} of all chronic HCV infections worldwide. Patients with HCV genotype 4 have been reported to have poor treatment responses to PEGylated interferon and ribavirin regimens. Recently a single tablet, fixed-dose combination ofsofos- buvir, an RNA-directed RNA polymerase (NS5B) inhibitor, and ledipasvir, a nonstructural protein 5A (NS5A) inhibitor; has been approved for treatment of chronic HCV infection. Two studies using the fixed-dose combination in chronic HCV genotype 4 for 12 weeks reported sustained virologic response rates at 12 weeks (SVR12) of 93-95{\%}. Data also support the use of ledipasvir/sofosbuvir in chronic HCV genotype 4 and HIV co-infection. Administered as a single once-daily oral regimeni, this ribavirin- And interferon-free regimen is well tolerated, with low potential for adverse effects and represents a significant advancement in the treatment of chronic HCV genotype 4 infection.",
keywords = "Directed RNA polymerase (NS5B) inhibitors, Fixed-dose combination, HCV nonstructural protein 5A (NS5A) inhibitors, Hepatitis C virus, Ledipasvir/sofosbuvir, RNA",
author = "V. Nehra and Tan, {E. M.} and Stacey Rizza and Zelalem Temesgen",
year = "2016",
month = "2",
day = "1",
doi = "10.1358/dot.2016.52.2.2449840",
language = "English (US)",
volume = "52",
pages = "111--117",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "2",

}

TY - JOUR

T1 - Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection

AU - Nehra, V.

AU - Tan, E. M.

AU - Rizza, Stacey

AU - Temesgen, Zelalem

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Hepatitis C virus (HCV) genotype 4 accounts for 8-13% of all chronic HCV infections worldwide. Patients with HCV genotype 4 have been reported to have poor treatment responses to PEGylated interferon and ribavirin regimens. Recently a single tablet, fixed-dose combination ofsofos- buvir, an RNA-directed RNA polymerase (NS5B) inhibitor, and ledipasvir, a nonstructural protein 5A (NS5A) inhibitor; has been approved for treatment of chronic HCV infection. Two studies using the fixed-dose combination in chronic HCV genotype 4 for 12 weeks reported sustained virologic response rates at 12 weeks (SVR12) of 93-95%. Data also support the use of ledipasvir/sofosbuvir in chronic HCV genotype 4 and HIV co-infection. Administered as a single once-daily oral regimeni, this ribavirin- And interferon-free regimen is well tolerated, with low potential for adverse effects and represents a significant advancement in the treatment of chronic HCV genotype 4 infection.

AB - Hepatitis C virus (HCV) genotype 4 accounts for 8-13% of all chronic HCV infections worldwide. Patients with HCV genotype 4 have been reported to have poor treatment responses to PEGylated interferon and ribavirin regimens. Recently a single tablet, fixed-dose combination ofsofos- buvir, an RNA-directed RNA polymerase (NS5B) inhibitor, and ledipasvir, a nonstructural protein 5A (NS5A) inhibitor; has been approved for treatment of chronic HCV infection. Two studies using the fixed-dose combination in chronic HCV genotype 4 for 12 weeks reported sustained virologic response rates at 12 weeks (SVR12) of 93-95%. Data also support the use of ledipasvir/sofosbuvir in chronic HCV genotype 4 and HIV co-infection. Administered as a single once-daily oral regimeni, this ribavirin- And interferon-free regimen is well tolerated, with low potential for adverse effects and represents a significant advancement in the treatment of chronic HCV genotype 4 infection.

KW - Directed RNA polymerase (NS5B) inhibitors

KW - Fixed-dose combination

KW - HCV nonstructural protein 5A (NS5A) inhibitors

KW - Hepatitis C virus

KW - Ledipasvir/sofosbuvir

KW - RNA

UR - http://www.scopus.com/inward/record.url?scp=84969627330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969627330&partnerID=8YFLogxK

U2 - 10.1358/dot.2016.52.2.2449840

DO - 10.1358/dot.2016.52.2.2449840

M3 - Article

C2 - 27092340

AN - SCOPUS:84969627330

VL - 52

SP - 111

EP - 117

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 2

ER -